RECRUITING

Using FAPI PET/MRI to Evaluate Prostate Cancer

Talk to us

Conditions

Prostate Cancer Metastatic DiseaseProstate Cancers

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.

Official Title

Novel FAP-targeted Approach to Metastatic Prostate Cancer

Quick Facts

Study Start:2024-12
Study Completion:2026-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06675357

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 years or older
  2. * Able and willing to provide informed consent
  3. * Known diagnosis of prostate cancer with established or suspected non-osseous, non-nodal metastases
  4. * Scheduled for standard-of-care PSMA PET
  5. * Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases
  6. * Willing and able to undergo PET/MRI as part of this research
  1. * Unable or unwilling to provide informed consent
  2. * Contraindication(s) to or inability to undergo PET/MRI
  3. * Participants for whom PET/MRI will delay timely delivery of treatment
  4. * Participants requiring intravenous (IV) conscious sedation for imaging care; those requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
  5. * Have their own prescription for the medication
  6. * The informed consent process is conducted prior to the self-administration of this medication
  7. * Come to the research visit with a driver

Contacts and Locations

Study Contact

Suzanne Hanson
CONTACT
608-282-8349
Radstudy@uwhealth.org

Principal Investigator

Ali Pirasteh, MD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

University of Wisconsin
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Ali Pirasteh, MD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12
Study Completion Date2026-10

Study Record Updates

Study Start Date2024-12
Study Completion Date2026-10

Terms related to this study

Additional Relevant MeSH Terms

  • Prostate Cancer Metastatic Disease
  • Prostate Cancers